Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of HLX208 in BRAF-mutant refractory primary intracranial tumors
CTR20212465Phase 2Terminated
- Sponsor
- Suzhou Runxin Biotechnology
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX208 in brain neoplasm, sponsored by Suzhou Runxin Biotechnology. Started Dec 2021; status: terminated.
02
Drugs
HLX208
03
Conditions
brain neoplasm
Beyond the preview
Go deeper on CTR20212465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212465.